Cyberknife stereostatic radiation for low risk prostrate cancer has found most patients had disease-free survival after five years, with little toxicity, results that researchers say could help bolster support for treatment.
It's no longer investigational or experimental therapy says study co-author, Dr.Debra E. Freeman , radiation oncologist, Cyberknife Centers, Tampa Bay, Florida.
It is felt slower growing "indolent" prostrate cancers respond better to hypofractionated treatments, as opposed to radiotherapy treatments.
Dr.Freeman commented toxic side effects from zapping the prostrate were also rare, with no rectal bleeding or significant damage to the bladder.
The greater availability of Cyberknife could increase the menu of options for many patients. And we know of the performance of Cyberknife in treating brain tumors.
Acknowledgment: www.dotmed.com Geoff.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment